Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data

 
• By Emily Hayes

Stock soars yet again with a positive data update for immuno-oncology star NKTR-214, a better-than-expected fourth quarter and catalysts for other pipeline candidates coming soon.

Honey - natural honey

Nektar Therapeutics' data update for the up-and-coming immuno-oncology candidate NKTR-214 – just partnered in a high-priced deal with Bristol-Myers Squibb Co. – along with better-than-expected earnings revved up even more excitement and expectations among investors.

The company's fourth quarter and full year 2017 earnings call late on March 1 followed on the heels of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.